enovid (NONS) was approved as a medical device in Israel and Bahrain and received a CE mark in the EU.
It is not approved in Canada yet.
Lab testing results
In-vitro studies, done by an external virology lab* confirms the virucidal activity of enovid.
Human testing results
In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19, SaNOtize’s early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads. The average viral log reduction in the first 24 hours was 1.362, which corresponds to a decline of about 95%. Within 72 hours, the viral load dropped by more than 99%. The majority of these patients had been infected with the UK variant, which is considered a variant of concern.
Data was published at the Journal of Infection:
* Institute of Antiviral Research, Utah State University, Logan, Utah , USA